Positive preliminary results from tivozanib-paclitaxel combination Phase 1b trial in

[News]

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced preliminary results from an ongoing Phase 1b clinical trial evaluating the company's lead product candidate, tivozanib, a highly potent and selective inhibitor of VEGF receptors 1, 2, and 3, in combination with paclitaxel (Taxol®), a standard chemotherapy regimen, in patients with metastatic breast cancer.

More... (http://www.news-medical.net/news/20101210/Positive-preliminary-results-from-tivozanib-paclitaxel-combination-Phase-1b-trial-in-metastatic-breast-cancer.aspx)